Title: AML-288 The Result of Post Chemotherapy Bone Marrow Recovery in Patients With Acute Leukemia and Lymphoid Malignancies
Abstract: S286LDAC in 5 patients, and decitabine (DAC) in 1 patient.The overall composite CR rate (CCR) was 59% (n=10/17), including 1 patient with incomplete counts recovery (CRi).Molecular MRD negativity was achieved in 6/10 complete responders.Reasons for treatment discontinuation were disease progression/refractoriness (n=10), HSCT (n=4), and unrelated liver disease (n=1).Median event-free and overall survival (EFS, OS) for the whole cohort were 11.8 and 11.9 months, respectively.A detrimental impact of FLT3-ITD mutation on CR rate, EFS, and OS was highlighted.Treatment was overall well tolerated, myelosuppression being predictably the most common therapy-related adverse event.